http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101471047-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 |
| filingDate | 2012-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101471047-B1 |
| titleOfInvention | Improved process for preparation of highly pure bosentan |
| abstract | The present invention relates to an improved preparation method of high-purity bosentan which is used as a therapeutic agent for pulmonary arterial hypertension (PAH) by dual endo-receptor antagonistic action. In the production process of the present invention, by using an ethylene glycol compound in which one of the hydroxyl groups is protected with a heterocyclic group such as tetrahydropyran (THP) or tetrahydrofuran (THF) in the coupling reaction, The production of ethylene glycol dimer and 6-hydroxy by-product, which have been problematic, is completely eliminated, so that high-purity bosentan can be obtained at a high yield without a high purification process. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020022546-A1 |
| priorityDate | 2012-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 94.